Physician profile
Kate J Ray
NPI 1073794285
$8,095.22
in general payments reported to CMS, 2019-2025
28 companies · $3,206 in 2025
The $3,206 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Registered Nurse) providers received nationally (typical 2025 total: $137).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $317 · 2022: $430 · 2023: $1,046 · 2024: $3,096 · 2025: $3,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,221 · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,220.85 |
| Education | $127.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,028.16 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $860.53 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $692.73 | 2022-2024 | Spravato, Invega |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $673.19 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $526.42 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $517.21 | 2024-2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $462.09 | 2021-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $437.39 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Corium, LLC | $419.91 | 2022-2025 | Azstarys, Adlarity |
| Axsome Therapeutics, INC. | $419.85 | 2023-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $355.24 | 2021-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $354.39 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $276.80 | 2023-2025 | Trintellix |
| Almatica Pharma LLC | $243.26 | 2021-2025 | Loreev Xr, Gralise |
| Alkermes, INC. | $234.90 | 2022-2025 | Aristada, Lybalvi |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $94.23 | 2024-2025 | Dyanavel Xr |
| Neos Therapeutics, Lp | $90.16 | 2022-2025 | Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $89.18 | 2025 | Jornay Pm |
| Harmony Biosciences LLC | $47.61 | 2025 | |
| Sunovion Pharmaceuticals INC. | $44.09 | 2021 | |
| Ironshore Pharmaceuticals INC. | $40.81 | 2022-2023 | Jornay Pm |
| Bausch Health US, LLC | $33.74 | 2022 | |
| Jazz Pharmaceuticals INC. | $33.32 | 2021-2022 | |
| Noven Therapeutics, LLC | $32.57 | 2024 | Xelstrym, Secuado |
| Merck Sharp & Dohme LLC | $26.84 | 2021-2023 | Belsomra |
| Axonics, INC. | $25.10 | 2024 | Axonics |
| Eisai INC. | $21.58 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.92 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kate Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.